Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date

BACKGROUND: Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a novel class of pharmacotherapeutics for type 2 diabetes management that work by reducing renal reabsorption of glucose. Ipragliflozin is a potent, selective SGLT-2 inhibitor used for the management of type 2 diabetes. OBJECTIVE: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkabbani, Wajd, Gamble, John-Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286902/
https://www.ncbi.nlm.nih.gov/pubmed/34285473
http://dx.doi.org/10.2147/DDDT.S281602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286902/
https://www.ncbi.nlm.nih.gov/pubmed/34285473
http://dx.doi.org/10.2147/DDDT.S281602

Ejemplares similares